--- title: "UnitedHealth Remarks 2" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/39597038.md" description: "Condition returns to $390 = Probability in the second half of 2027–early 2028: High (70%+)..." datetime: "2026-03-28T09:22:30.000Z" locales: - [en](https://longbridge.com/en/topics/39597038.md) - [zh-CN](https://longbridge.com/zh-CN/topics/39597038.md) - [zh-HK](https://longbridge.com/zh-HK/topics/39597038.md) author: "[小马哥的交易员](https://longbridge.com/en/profiles/15302149.md)" --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/topics/39597038.md) | [繁體中文](https://longbridge.com/zh-HK/topics/39597038.md) # UnitedHealth Remarks 2 ## Conditions Back to $390 = Second half of 2027 – early 2028 Probability: High (70%+), but must meet 4 core conditions 1\. First, calculate: What $390 corresponds to • Target: $390 • Corresponding reasonable P/E: 22x (upper limit of reasonable range) • Required EPS: $390 ÷ 22 ≈ $17.73 2\. Timeline (most likely path) • Full year 2026: Bottom recovery period ◦ Target: MCR from 89.1% → 87.5–88.0% ◦ EPS: $17.75 (company guidance) ◦ Stock price: $300–$350 (P/E 17–20x) • First half of 2027: Inflection point confirmation period ◦ MCR stabilizes at 86–87%, profit margin recovers to 5.5%+ ◦ Valuation recovers to 19–21x ◦ Stock price: $350–$380 • Second half of 2027 – early 2028: Valuation + earnings double play ◦ MCR returns to 84–85% (healthy level) ◦ EPS revised up to \*\*$18.5–$19.0\*\* ◦ P/E returns to 21–22x ◦ Stock price: $390+ 3\. The 4 core conditions that must be met (all are essential) 1️⃣ MCR continuous improvement (most critical) • 2026Q2: MCR <88.0% (quarter-on-quarter decline) • Full year 2026: MCR ≤87.5% • Full year 2027: MCR ≤85.0% (back to historical healthy range) • Triggers: Premium increases, network optimization, cost control taking effect 2️⃣ Profit and margin recovery • 2026: Operating profit margin from 4.2% → 5.5%+ • 2027: Profit margin returns to 6.0–6.5% (close to historical average) • EPS: 2026≥$17.75; 2027≥$18.5; 2028≥$19.5 3️⃣ CMS policy and regulatory environment neutral • Medicare Advantage (MA) payment policy does not worsen further • V28 cost-cutting impact fully dissipates by 2027 • No new strong pricing/claim ratio pressure policies for healthcare 4️⃣ Valuation recovery + market sentiment improvement • Healthcare sector valuation recovers from low levels to historical center • Market shifts from "fearing MCR" to "recognizing leader's recovery capability" • P/E from current 14.6x → 21–22x (upper limit of reasonable range) 4\. Probability assessment • High probability (70%+): ◦ Company proactively shrinks membership, optimizes network, raises premiums; MCR recovery path is clear ◦ Optum business is resilient, cash flow is stable, supporting recovery ◦ Buffett's holdings provide endorsement; long-term capital recognizes leader's value • Risks (30%): ◦ Medical costs exceed expectations, MCR rebounds ◦ CMS further cuts MA payments ◦ High macro interest rates suppress defensive sector valuations 5\. Key observation points (you can track) • 2026Q2 earnings report (July): Whether MCR <88% (core inflection point signal) • 2026Q4 earnings report (Jan 2027): Whether full-year MCR ≤87.5% • 2027Q2 earnings report: Whether MCR <86%, profit margin \>6% ## Tracking UnitedHealth stock price back to $390 target Tracking condition checklist (concise and directly comparable) 1\. Target corresponding valuation • Target stock price: $390 • Corresponding P/E: 22x (upper limit of reasonable range) • Corresponding EPS: ≥$17.75 • Path to achieve: EPS stabilizes + P/E recovers from 14.6x to 22x 2\. Core conditions that must be met (all are essential) 1. Medical Cost Ratio (MCR) continuous improvement (most critical) • Full year 2026 consolidated MCR: ≤ 87.5% • Full year 2027 consolidated MCR: Falls back to 84.0%–85.0% • MA business MCR: Falls back from 92% to ≤ 86% • Observation signal: Quarterly MCR declines consecutively quarter-on-quarter, no rebound 1. Profit and margin return to healthy levels • Full year 2026 EPS: ≥ $17.75 (meets company guidance) • Net profit margin: Recovers from 2.7% to ≥ 5.0% • Full year 2027 EPS: ≥ $18.50 • Free cash flow: ≥ $14.2 billion in 2026, continues to grow in 2027 1. CMS policy does not worsen • 2027 CMS MA rate final rule: Not significantly below expectations • Risk adjustment (V28) cost-cutting impact: Largely cleared by 2027 • No new harsh regulations, coding restrictions, or penalty policies targeting MA 1. External shocks and internal issues cleared • Change Healthcare cyberattack impact completely eliminated • DOJ-related investigations concluded, no massive fines or business bans • Medical service utilization, medical inflation return to normal range 1. Valuation recovery conditions • Market no longer assigns extreme pessimistic discount to healthcare stocks • Institutional capital flows back, P/E recovers from current 14–15x → to 19–22x • Broad market and interest rate environment stable, not suppressing defensive sector valuations 3\. Timeline and corresponding stock price pace Phase 1: 2026 Q2–Q3 (bottoming confirmation) • Key observation: 2026 Q2 earnings report (July) • Trigger signal: MCR < 88.0% • Target stock price range: $280 – $320 Phase 2: End of 2026 – first half of 2027 (valuation recovery) • Key observation: Full year 2026 earnings report + 2027 Q1 earnings report • Trigger signal: Full-year MCR ≤ 87.5%, EPS meets target • Target stock price range: $320 – $380 Phase 3: Second half of 2027 – early 2028 (reaching $390) • Key observation: 2027 Q2–Q3 earnings reports • Trigger signal: MCR stable at 84%–85%, EPS revised up • Target stock price: $390+ 4\. One-sentence judgment As long as MCR continues to decline and EPS stabilizes from 2026 to 2027, it is a high-probability event for UnitedHealth to reach $390 in the second half of 2027 to early 2028. ### Related Stocks - [Berkshire Hathaway Inc. (BRK.A.US)](https://longbridge.com/en/quote/BRK.A.US.md) - [UnitedHealth Group Incorporated (UNH.US)](https://longbridge.com/en/quote/UNH.US.md) - [Berkshire Hathaway Inc. (BRK.B.US)](https://longbridge.com/en/quote/BRK.B.US.md) - [XL2CSOPBRKB (07777.HK)](https://longbridge.com/en/quote/07777.HK.md)